Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C20H25N3O4 |
| Molecular Weight | 371.4302 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=C2N(C=C(C(O)=O)C(=O)C2=CC=C1N3C[C@@H](C)C[C@H](N)C3)C4CC4
InChI
InChIKey=AVPQPGFLVZTJOR-RYUDHWBXSA-N
InChI=1S/C20H25N3O4/c1-11-7-12(21)9-22(8-11)16-6-5-14-17(19(16)27-2)23(13-3-4-13)10-15(18(14)24)20(25)26/h5-6,10-13H,3-4,7-9,21H2,1-2H3,(H,25,26)/t11-,12-/m0/s1
| Molecular Formula | C20H25N3O4 |
| Molecular Weight | 371.4302 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Nemonoxacin is a non-fluorinated quinolone antibiotic in clinical development in an oral and intravenous formulation. It exhibits potent antibacterial activities against Gram-positive, Gram-negative, and atypical pathogens, especially methicillin-resistant Staphylococcus aureus. The molecule inhibits bacterial DNA synthesis by forming a ternary complex with a DNA molecule and gyrase and topoisomerase IV enzymes, thus blocking bacterial DNA supercoiling. Nemonoxacin is developed by TaiGen Biotechnology Company and has reached worldwide approval in 2014 and is marketed under the name Taigexyn®.
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 15:51:04 UTC 2023
by
admin
on
Sat Dec 16 15:51:04 UTC 2023
|
| Record UNII |
P94L0PVO94
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-ATC |
J01MB08
Created by
admin on Sat Dec 16 15:51:05 UTC 2023 , Edited by admin on Sat Dec 16 15:51:05 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C174838
Created by
admin on Sat Dec 16 15:51:05 UTC 2023 , Edited by admin on Sat Dec 16 15:51:05 UTC 2023
|
PRIMARY | |||
|
C543520
Created by
admin on Sat Dec 16 15:51:05 UTC 2023 , Edited by admin on Sat Dec 16 15:51:05 UTC 2023
|
PRIMARY | |||
|
378746-64-6
Created by
admin on Sat Dec 16 15:51:05 UTC 2023 , Edited by admin on Sat Dec 16 15:51:05 UTC 2023
|
PRIMARY | |||
|
8789
Created by
admin on Sat Dec 16 15:51:05 UTC 2023 , Edited by admin on Sat Dec 16 15:51:05 UTC 2023
|
PRIMARY | |||
|
11993740
Created by
admin on Sat Dec 16 15:51:05 UTC 2023 , Edited by admin on Sat Dec 16 15:51:05 UTC 2023
|
PRIMARY | |||
|
5079
Created by
admin on Sat Dec 16 15:51:05 UTC 2023 , Edited by admin on Sat Dec 16 15:51:05 UTC 2023
|
PRIMARY | |||
|
DB06600
Created by
admin on Sat Dec 16 15:51:05 UTC 2023 , Edited by admin on Sat Dec 16 15:51:05 UTC 2023
|
PRIMARY | |||
|
DTXSID10958907
Created by
admin on Sat Dec 16 15:51:05 UTC 2023 , Edited by admin on Sat Dec 16 15:51:05 UTC 2023
|
PRIMARY | |||
|
CHEMBL1213456
Created by
admin on Sat Dec 16 15:51:05 UTC 2023 , Edited by admin on Sat Dec 16 15:51:05 UTC 2023
|
PRIMARY | |||
|
Nemonoxacin
Created by
admin on Sat Dec 16 15:51:05 UTC 2023 , Edited by admin on Sat Dec 16 15:51:05 UTC 2023
|
PRIMARY | |||
|
300000034273
Created by
admin on Sat Dec 16 15:51:05 UTC 2023 , Edited by admin on Sat Dec 16 15:51:05 UTC 2023
|
PRIMARY | |||
|
P94L0PVO94
Created by
admin on Sat Dec 16 15:51:05 UTC 2023 , Edited by admin on Sat Dec 16 15:51:05 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET ORGANISM->INHIBITOR |
|
||
|
TARGET ORGANISM->INHIBITOR |
|
||
|
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET ORGANISM->INHIBITOR |
|
||
|
TARGET ORGANISM->INHIBITOR |
|
||
|
|
TARGET -> INHIBITOR |
|
||
|
|
SALT/SOLVATE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
